<table>
<thead>
<tr>
<th>Clinical Trial Number</th>
<th>Title</th>
<th>Phase</th>
<th>Sites</th>
</tr>
</thead>
</table>
| N/A                   | Collaborative Ocular Oncology Group Uveal Melanoma Validation Study Number 2 (COOG2) | Observational | Multiple Sites J. William Harbour, MD  
U. Miami Bascom Palmer Eye Institute  
Contact: Christina Decatur; 305-326-6020 CDecatur@med.miami.edu |
| NCT02678572           | Percutaneous Hepatic Perfusion in Patients with Hepatic-Dominant Ocular Melanoma (FOCUS) | III     | Multiple Sites Jonathan Zager, MD  
Moffit Cancer Center  
Contact: Jennifer Ayala; 212-489-2100 ext 249 jayala@delcath.com |
| NCT03472586           | Ipilimumab and Nivolumab with Immunoembolization in Treating Patients with Metastatic Uveal Melanoma in the Liver | II      | Sidney Kimmel Cancer Center at Thomas Jefferson University  
Marlana Orloff, MD; 215-955-8874 mmo@jefferson.edu |
| NCT03528408*          | Study of Adjuvant Ipilimumab and Nivolumab in Subjects with High-Risk Ocular Melanoma | II      | University of California San Francisco  
Katy Tsai, MD  
Contact: Mario Velez; 415-353-7862 Mario.Velez@ucsf.edu |
| NCT03712904           | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients with Uveal Melanoma | II      | Sidney Kimmel Cancer Center at Thomas Jefferson University  
Wenyin Shi, MD, PhD; 215-955-6702 wenyin.shi@jefferson.edu |
| NCT03850691           | Radiation and Combination Immunotherapy for Melanoma                     | II      | Masonic Cancer Center at University of Minnesota  
Evidio Domingo Musibay, MD; 612-624-5373 musib024@umn.edu |
| NCT03070392           | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | II      | Immunocore Ltd  
Shaad Abdullah, MD; 484-534-5261 clinicaltrials@immunocore.com |
| NCT02831933           | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma (ENSIGN) | II      | Houston Methodist Hospital  
Eric Bernicker, MD; 713-441-0629 ccresearch@houstonmethodist.org |
| NCT03467516           | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma | II      | UPMC Hillman Cancer Center  
Samantha Perkins, PA-C; 412-623-5960 perkinssj@upmc.edu  
Krystle Eaton, BSN; 412-623-7957 |

This is an active clinical trial list retrieved from [www.clinicaltrials.gov](http://www.clinicaltrials.gov) on March 4, 2020. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Study Title</th>
<th>Phase</th>
<th>Institution/Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02068586</td>
<td>Adjuvant Sunitinib or Valproic Acid in High-Risk Patients with Uveal Melanoma</td>
<td>II</td>
<td><a href="mailto:mientkiewicz@upmc.edu">mientkiewicz@upmc.edu</a></td>
</tr>
<tr>
<td>NCT03207347</td>
<td>A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient NEoplams (UF-STO-ETI-001)</td>
<td>II</td>
<td>University of Florida</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Erin Monari, PhD; 352-273-8128 <a href="mailto:PMO@cancer.ufl.edu">PMO@cancer.ufl.edu</a></td>
</tr>
<tr>
<td>NCT02519322</td>
<td>Neoadjuvant and Adjuvant Checkpoint Blockade</td>
<td>II</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rodabe Amaria; 713-792-2921 <a href="mailto:rnamaria@mdanderson.org">rnamaria@mdanderson.org</a></td>
</tr>
<tr>
<td>NCT02913417</td>
<td>Yttrium90, Ipilimumab, &amp; Nivolumab for Uveal Melanoma with Liver Metastasis</td>
<td>I/II</td>
<td>Multiple Sites</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kevin B Kim, MD; 415-885-8600 <a href="mailto:KimKB@sutterhealth.org">KimKB@sutterhealth.org</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Laurel Brechtel; 415-600-1654 <a href="mailto:brechtelLA@cpmcri.org">brechtelLA@cpmcri.org</a></td>
</tr>
<tr>
<td>NCT03947385</td>
<td>Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</td>
<td>I/II</td>
<td>Multiple Sites</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Julie Hambleton, MD; 650-262-3603 <a href="mailto:Jhambleton@ideayabio.com">Jhambleton@ideayabio.com</a></td>
</tr>
<tr>
<td>NCT03297424</td>
<td>A Study of PLX2853 in Advanced Malignancies</td>
<td>I/II</td>
<td>Multiple Sites</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Paul Watkins; 510-647-4151 <a href="mailto:PWatkins@plexxikon.com">PWatkins@plexxikon.com</a></td>
</tr>
<tr>
<td>NCT03865212</td>
<td>Modified Virus VSV-IFNbeta-TYRP1 in Treating Patients with Stage III-IV Melanoma</td>
<td>I</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Roxana S Dronca, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical Trials S. Referral Office; 855-776-0015</td>
</tr>
<tr>
<td>NCT02768766</td>
<td>Intermittent Selumetinib for Uveal Melanoma</td>
<td>I</td>
<td>Multiple Sites</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lisa Olmos, RN; 212-342-5162 <a href="mailto:cancerclinicaltrials@cumc.columbia.edu">cancerclinicaltrials@cumc.columbia.edu</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Richard Carvajal, MD; 646-317-6354 <a href="mailto:Rcd2150@cumc.columbia.edu">Rcd2150@cumc.columbia.edu</a></td>
</tr>
<tr>
<td>NCT04082962</td>
<td>Dexamethasone Implant for Retinal Detachment in Uveal Melanoma</td>
<td>I</td>
<td>Massachusetts Eye and Ear Infirmary</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gary A Lamoureux, BS; 617-573-3067 <a href="mailto:gary_lamoureux@meei.harvard.edu">gary_lamoureux@meei.harvard.edu</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anne Marie Lane, MPH; 617-573-3735 <a href="mailto:alane@meei.harvard.edu">alane@meei.harvard.edu</a></td>
</tr>
</tbody>
</table>

This is an active clinical trial list retrieved from www.clinicaltrials.gov on March 4, 2020. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Title</th>
<th>Location</th>
<th>Principal Investigator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03068624</td>
<td>Uveal Melanoma T Cell Therapy</td>
<td>MD Anderson Cancer Center</td>
<td>Sapna P. Patel, MD; 713-792-2921</td>
</tr>
<tr>
<td>NCT03025256</td>
<td>Intravenous and Intrathecal Nivolumab in Treating Patients with Leptomeningeal Disease</td>
<td>MD Anderson Cancer Center</td>
<td>Isabella C. Glitza, MD; 713-792-2921 <a href="mailto:ICGlitza@mdanderson.org">ICGlitza@mdanderson.org</a></td>
</tr>
<tr>
<td>NCT00986661</td>
<td>A Study to Assess PV-10 Chemoablation of Cancer of the Liver</td>
<td>Multiple Sites</td>
<td>Eric Wachter, PhD; 865-769-4011 ext 23 <a href="mailto:wachter@pvct.com">wachter@pvct.com</a></td>
</tr>
<tr>
<td>NCT03635632</td>
<td>C7R-GD2.CART Cells for Patients with Relapsed or Refractory Neuroblastome and Other GD2 Positive Cancers (GAIL-N)</td>
<td>Baylor College of Medicine</td>
<td>Bilal Omer, MD; 832-824-6855 <a href="mailto:bomer@bcm.edu">bomer@bcm.edu</a></td>
</tr>
<tr>
<td>NCT03752398</td>
<td>A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)</td>
<td>Multiple Sites</td>
<td>David Liebowitz, MD; 858-617-6160 <a href="mailto:dliebowitz@xencor.com">dliebowitz@xencor.com</a> Phuong Lee; 858-480-3115 <a href="mailto:plee@xencor.com">plee@xencor.com</a></td>
</tr>
<tr>
<td>NCT01925599</td>
<td>BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma</td>
<td>Retina Consultants of Houston</td>
<td>Amy C. Schefler, MD; 713-524-3434 <a href="mailto:acsm@houstonretina.com">acsm@houstonretina.com</a> Cassie Cone, BA; 713-524-3434 <a href="mailto:ccone@houstonretina.com">ccone@houstonretina.com</a></td>
</tr>
<tr>
<td>NCT00344799</td>
<td>Cytogenetic Study of Ocular Melanoma</td>
<td>Jules Stein Eye Institute</td>
<td>Brenda Rangel; 310-794-9962 <a href="mailto:Brangel@jsei.ucla.edu">Brangel@jsei.ucla.edu</a></td>
</tr>
<tr>
<td>NCT01930968</td>
<td>Definity for Ultrasound of Intraocular Tumors</td>
<td>Emory University</td>
<td>Hans Grossniklaus, MD; 404-778-4611 ext 4613 <a href="mailto:ophtheg@emory.edu">ophtheg@emory.edu</a> Alcides Fernandes, MD; 404-778-2421 <a href="mailto:afilho@emory.edu">afilho@emory.edu</a></td>
</tr>
<tr>
<td>NCT03941379</td>
<td>A Registry of Patients with Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)</td>
<td>Multiple Sites</td>
<td>Rochelle Summerfelt, MS; 773-855-8157 <a href="mailto:rsummerfelt@aurabiosciences.com">rsummerfelt@aurabiosciences.com</a> Abhijit Narvekar, MBBS, MS, DPM; 617-250-7255 <a href="mailto:anarvekar@aurabiosciences.com">anarvekar@aurabiosciences.com</a></td>
</tr>
</tbody>
</table>

*Inclusion criteria include DecisionDx-UM Class 2 test result

This is an active clinical trial list retrieved from [www.clinicaltrials.gov](http://www.clinicaltrials.gov) on March 4, 2020. This list is being provided for information purposes only, and Castle Biosciences, Inc. does not provide any representation or warranty as to its accuracy, completeness or fitness for use; make any endorsement of any trials included in this list; or assume any obligation to update this list.